Northern Trust Corp Neurocrine Biosciences Inc Transaction History

Northern Trust Corp

$572 Billion
Q1 2024

A detailed history of Northern Trust Corp transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Northern Trust Corp holds 715,068 shares of NBIX stock, worth $98.4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

715,068

Previous 807,281 11.42%

Holding current value

$98.4 Million

Previous $106 Million 7.28%

% of portfolio

0.02%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$130.4 - $143.74 $12 Million - $13.3 Million	-92,213 Reduced 11.42%	715,068 $98.6 Million
Q4 2023 Feb 13, 2024	SELL	$106.07 - $132.76 $3.83 Million - $4.79 Million	-36,062 Reduced 4.28%	807,281 $106 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $457,783 - $570,159	-4,869 Reduced 0.57%	843,343 $94.9 Million
Q2 2023 Aug 11, 2023	SELL	$89.53 - $104.87 $2.45 Million - $2.87 Million	-27,398 Reduced 3.13%	848,212 $80 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $1.32 Million - $1.73 Million	14,068 Added 1.63%	875,610 $88.6 Million

Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $361,460 - $430,352	3,387 Added 0.39%	861,542 $103 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $1.12 Million - $1.31 Million	-12,167 Reduced 1.4%	858,155 $91.1 Million
Q2 2022 Aug 12, 2022	SELL	$75.79 - $100.07 $967,762 - $1.28 Million	-12,769 Reduced 1.45%	870,322 $84.8 Million
Q1 2022 May 13, 2022	BUY	$72.45 - $94.81 $628,866 - $822,950	8,680 Added 0.99%	883,091 $82.8 Million
Q4 2021 Feb 08, 2022	SELL	$79.65 - $106.22 $3.14 Million - $4.18 Million	-39,388 Reduced 4.31%	874,411 $74.5 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $1.55 Million - $1.78 Million	17,940 Added 2.0%	913,799 $87.6 Million
Q2 2021 Aug 13, 2021	SELL	$89.43 - $102.27 $5.83 Million - $6.66 Million	-65,144 Reduced 6.78%	895,859 $87.2 Million
Q1 2021 May 12, 2021	BUY	$87.57 - $119.4 $28.6 Million - $39.1 Million	327,101 Added 51.6%	961,003 $93.5 Million
Q4 2020 Feb 11, 2021	SELL	$86.91 - $108.33 $715,530 - $891,880	-8,233 Reduced 1.28%	633,902 $60.8 Million
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $3.52 Million - $4.94 Million	-36,572 Reduced 5.39%	642,135 $61.7 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $6.99 Million - $10.7 Million	82,118 Added 13.76%	678,707 $82.8 Million
Q1 2020 May 14, 2020	BUY	$75.11 - $113.76 $3.3 Million - $5 Million	43,924 Added 7.95%	596,589 $51.6 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $9.72 Million - $13.3 Million	112,033 Added 25.43%	552,665 $59.4 Million
Q3 2019 Nov 13, 2019	SELL	$83.82 - $101.5 $522,282 - $632,446	-6,231 Reduced 1.39%	440,632 $39.7 Million
Q2 2019 Aug 13, 2019	BUY	$72.24 - $91.27 $11,702 - $14,785	162 Added 0.04%	446,863 $37.7 Million
Q1 2019 May 13, 2019	BUY	$69.31 - $91.53 $413,919 - $546,617	5,972 Added 1.36%	446,701 $39.4 Million
Q4 2018 Feb 12, 2019	BUY	$68.32 - $124.36 $75,151 - $136,796	1,100 Added 0.25%	440,729 $31.5 Million
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $841,172 - $1.07 Million	-8,507 Reduced 1.9%	439,629 $54.1 Million
Q2 2018 Sep 18, 2018	SELL	$75.3 - $105.99 $421,604 - $593,438	-5,599 Reduced 1.23%	448,136 $44 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $2.26 Million - $3.19 Million	-30,066 Reduced 6.21%	453,735 $44.6 Million
Q1 2018 May 09, 2018	BUY	$75.88 - $92.43 $1.17 Million - $1.42 Million	15,395 Added 3.29%	483,801 $40.1 Million
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $437,511 - $579,985	7,475 Added 1.62%	468,406 $36.3 Million
Q3 2017 Nov 13, 2017	BUY	$47.97 - $61.28 $22.1 Million - $28.2 Million	460,931	460,931 $28.2 Million

Others Institutions Holding NBIX

# of Institutions

628

Shares Held

94.4M

Call Options Held

505K

Put Options Held

343K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Neurocrine Biosciences Inc Transaction History